This article has been updated to include information from a second SEC filing, filed by OpGen on Sept. 14.

NEW YORK (GenomeWeb) – OpGen late Wednesday filed a prospectus with the US Securities and Exchange Commission to sell up to $25 million of its common stock through Cowen and Co. on the Nasdaq, with initial sales to be limited to $11.5 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.